Matthias Leifgen

Dr. Jiajia Xu-Ganyecz

Jiajia Xu-Ganyecz studied biology with a focus on microbiology, immunology, virology and genetics at the Julius-Maximilians-University of Würzburg, where she received her PhD in tumor biology from the Department of Biochemistry and Molecular Biology. Her PhD thesis dealt with the identification of synthetic lethality in MYC tumors using next-generation sequencing.

Following her PhD, she worked in the patent department of a medical diagnostics company and in the business development department of a biopharmaceutical company. During her time in industry she gained valuable experience in FTO and prior art analyses, ans was involved in developing patent strategy in the fields of diagnostics, gene therapy and production of therapeutic proteins.

She assists in drafting patent and utility model applications, supporting prosecution proceedings, performing FTO, patent validity, infringement and prior art analyses. Through her academic and industrial experiences, she can draw on expertise especially in diagnostic , gene therapy and sequencing methods, in addition to drug development and computer-implemented inventions.

She is fluent in German, English and Chinese. She acquired the qualification of Chinese patent attorney in 2020 and advises Chinese-speaking clients on intellectual property matters.